Indeed, a number of HSP90 inhibitors such as AUY922 that do not significantly affect normal cell survival are currently in clinical studies for the treatment of various types of cancers including wild-type KRAS colon cancer [14–16]. Here, HSP90AA1 is linked to malignant colon neoplasm.